Latest Breaking News On - Investoren anteile - Page 1 : vimarsana.com
21st Austria weekly - Frequentis (17/08/2021)
boerse-social.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-social.com Daily Mail and Mail on Sunday newspapers.
21st Austria weekly - AT&S, Mayr-Melnhof, Andritz (03/08/2021)
boerse-social.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-social.com Daily Mail and Mail on Sunday newspapers.
21st Austria weekly - Marinomed, Andritz, ams Osram, Valneva (01/07/2021)
boerse-social.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-social.com Daily Mail and Mail on Sunday newspapers.
21st Austria weekly - Immofinanz; Marinomed, Valneva, FACC, AT&S, Lenzing (21/04/2021)
boerse-social.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-social.com Daily Mail and Mail on Sunday newspapers.
18.04.2021
Andritz: International technology Group Andritz has successfully started up a new 500 t/d Herb chemical recovery boiler at Kuantum Papers Limited in Saila Khurd, Hoshiapur district in the state of Punjab, India. The boiler is designed to handle a mixture of hardwood and agro-based black liquor and enables environmentally friendly and more energy-efficient operation compared to a conventional boiler with direct contact evaporator. Thus, the mill’s pulp production as well as the power-to-heat-ratio are substantially increased. The boiler also features a unique vertical air system to minimize air emissions.
Andritz: weekly performance:
-1.21%
Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that out of the initially enrolled 64 patients, all 62 patients included in the treatment cycles have now concluded the Phase II clinical trial e